Company intelligence / Profile preview

Hutchison Healthcare Holdings

Shanghai, Shanghai / Hong Kong, China

Ownership: Private
Development stage: Other

Overview

The group develops and markets pharmaceuticals in China, including novel oncology drugs, inflammation drugs (e.g., HMPL-004 for IBD showing Phase IIb efficacy), and consumer health products. Recent divestment of legacy cardiovascular business favoring innovative oncology/immune therapeutics commercialization

Therapeutic areas: CardiovascularGastroenterologyOncologyImmunology
Modalities: Small moleculeBiologicBotanical drugpossibly Antibody-drug conjugate
Industry: Biotech

Partnerships

AstraZeneca (Orpathys + Tagrisso combo for NSCLC)Shanghai Pharmaceuticals (JV in SHPL; recently reduced)

Beyond the preview

Go deeper on Hutchison Healthcare Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hutchison Healthcare Holdings.

Explore the full profile